The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...

The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...

Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) ...

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...

Symptoms and treatment options depend on the stage of your lung cancer along with what type of NSCLC you're diagnosed with. There are three primary types: adenocarcinoma, squamous cell carcinoma, and ...

That's less impressive than the 50% reduction in death in Merck's KEYNOTE-189 trial of Keytruda in non-squamous NSCLC – which was behind its approval for first-line NSCLC alongside chemo in 2018 ...